Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2026-01-26 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing significant updates to their clinical development strategy, including new efficacy objectives for their drug candidates (NFL-101 and NFL-102), mechanism of action findings, and intellectual property extensions. It is a corporate announcement detailing business and clinical progress, which falls under the category of general regulatory announcements or corporate news updates.
2026-01-26 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences titled 'NFL Biosciences significantly raises its efficacy targets for smoking cessation'. It details updates on clinical development strategies, drug candidates (NFL-101 and NFL-102), mechanism of action research, and intellectual property. It is not a periodic financial report, a transcript, or a governance document. It functions as a corporate announcement regarding business strategy and R&D progress, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-26 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 100% confidence The document is a press release from NFL Biosciences detailing the semi-annual report of its liquidity contract with Invest Securities for the second half of 2025. It provides specific data on share transactions (purchases and sales) and the remaining balance in the liquidity account. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth Paris to report on their share buyback/liquidity programs. Since it is a periodic report of transactions in own shares, it falls under the 'Transaction in Own Shares' category.
2026-01-06 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 93% confidence The document is a press release from NFL Biosciences announcing scientific results regarding their drug candidate NFL-101. It details the characterization of the drug, its regulatory implications, and the potential for a new patent. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As a general corporate announcement regarding business operations and R&D progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing scientific results regarding their drug candidate NFL-101. It details the completion of a characterization program, the strengthening of intellectual property, and the preparation of a new patent application. As this is a general corporate announcement regarding operational and scientific progress that does not fit into specific financial reporting categories like earnings, dividends, or board changes, it falls under the general regulatory filing/announcement category.
2025-12-08 English
Inside Information / Other news releases
Regulatory Filings Classification · 96% confidence The document is a press release from NFL Biosciences announcing an upcoming agenda for scientific milestones and results related to their drug candidate, NFL-101. It does not contain the actual financial results or the full reports themselves, but rather provides a schedule of future communications and scientific updates. As it is a general corporate announcement regarding business strategy and upcoming milestones that does not fit into specific categories like earnings releases or financial reports, it is best classified as a general regulatory filing/announcement.
2025-11-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.